| ClinicalTrials.gov Identifier |
| NCT03602079 |
| Institution Name |
| The University of Texas MD Anderson Cancer Center |
| Institution City |
| Houston |
| Institution State |
| Texas |
| Institution ZIP Code |
| 77030 |
| Institution Country |
| United States |
| Additional Institutions |
- Florida Cancer Specialists & Research Institute
Sarasota, Florida, United States, 34232
- Beth Israel Deaconess Medical Center Cancer Center
Boston, Massachusetts, United States, 02215
- Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
- Clinical Research Alliance, Inc.
Lake Success, New York, United States, 11042
- Stephenson Cancer Center
Oklahoma City, Oklahoma, United States, 73104
- Providence Cancer Institute
Portland, Oregon, United States, 97213
- Mary Crowley Cancer Research Centers - Medical City
Dallas, Texas, United States, 75230
- South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio, Texas, United States, 78229
- Virginia Cancer Specialist
Fairfax, Virginia, United States, 22031
|
| Principal Investigator |
| Jordi Rodon Ahnert, M.D., PhD |
| Principal Investigator Phone |
| (713) 563-1930 |
| Principal Investigator Email |
| yjiang@mdanderson.org |
| Additional Principal Investigators |
| Virginia Cancer Specialist
Contact: Alexander Spira, MD, PhD,FACP 703-280-5390 Alexander.Spira@usoncology.com |
| Study Coordinator |
| Yunfang (Jenny) Jiang |
| Study Coordinator Phone |
| (713) 794-1751 |
| Study Coordinator Email |
| yjiang@mdanderson.org |
| Additional Study Coordinators |
|
| Study Overview |
| Study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Cycles will continue until disease progression or unacceptable toxicity. |
| Enrollment Information |
| 102 |
| Study Start Date |
| 20180716 |
| Study End Date |
| 20200110 |
| Financial Assistance Available |
| No |
